| Baseline | 2 months* | 4 months* | 6 months* |
---|---|---|---|---|
Benzodiazepines (dose) | X | X | X | X |
Co medication | X | X | X | X |
Neurocognition (BACS) | X | X | X | X |
Psychophysiology | X | X | X | X |
Sleep assessment (PSG) | X | Â | Â | X |
Psychopathology (PANSS) | X | Â | Â | X |
Quality of life (WHO-5 and SWN-S) | X | X | X | X |
Withdrawal symptoms (BWSQ-2) | X | X | X | X |
Subjective sleep quality (PSQI) | X | Â | Â | X |
Social functioning (PSP) | X | X | X | X |
Laboratory tests | X | Â | Â | X |
Lifestyle factors | X | Â | Â | X |
Physical examination | X | Â | Â | X |
Sociodemographic characteristics | X | Â | Â | Â |
Plasma benzodiazepines | Â | Â | Â | X |
Adverse events | Â | X | X | X |